| Patent Number |
Title Of Patent |
Date Issued |
| RE38132 |
Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidine |
June 3, 2003 |
| A method treating or preventing inflammatory and immune cell-mediated diseases by the administration of certain novel and known small molecules. Exemplary of the novel compounds are those of the following structural formulas: ##STR1## ##STR2## |
| D492786 |
Adhesive patch |
July 6, 2004 |
|
| D492416 |
Adhesive patch |
June 29, 2004 |
|
| D481131 |
Adhesive patch |
October 21, 2003 |
|
| D480811 |
Adhesive patch |
October 14, 2003 |
|
| 7425629 |
Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
September 16, 2008 |
| A process for stereoselective synthesis of a compound of Formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as described herein. |
| 7417127 |
Antibodies specific for CD44v6 |
August 26, 2008 |
| The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid m |
| 7405225 |
Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for pr |
July 29, 2008 |
| Disclosed are compounds of formula (I): ##STR00001## wherein R.sub.1 and R.sub.2 are defined herein, which are useful as inhibitors of the kinase activity of the I.kappa.B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including au |
| 7375220 |
Method of treating diseases and conditions associated with an altered level of amyloid .beta. p |
May 20, 2008 |
| A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid .beta. peptides (A.beta.) and/or with a changed ratio of levels of A.beta. isoforms and/or with the formation of plaques containing amyloid .beta. peptide (A.beta.) isof |
| 7345074 |
Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide |
March 18, 2008 |
| Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. |
| 7335657 |
Cytokine inhibitors |
February 26, 2008 |
| Disclosed are compounds of formula (I) ##STR00001## Where Ar.sub.1, X, Y, Q, W, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.y are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases |
| 7329764 |
Substitute benzothiophene compounds |
February 12, 2008 |
| Disclosed are compounds of the formula I shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds ##STR00001## |
| 7326719 |
Cathepsin S inhibitors |
February 5, 2008 |
| This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention al |
| 7321041 |
1,6 Naphthyridines useful as inhibitors of SYK kinase |
January 22, 2008 |
| Disclosed are compounds of formula (I): ##STR00001## wherein R.sub.3, R.sub.5, R.sub.7 and R.sub.8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and in |
| 7304067 |
Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide |
December 4, 2007 |
| Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. |
| 7291733 |
Substituted tricyclic heterocycles and their uses |
November 6, 2007 |
| Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds # |
| 7285545 |
Cytokine inhibitors |
October 23, 2007 |
| Disclosed are compounds of formula (I) ##STR00001## which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processe |
| 7279475 |
Fluorinated di-aryl urea compounds |
October 9, 2007 |
| Disclosed are compounds of formula(I): ##STR00001## wherein R.sub.1, R.sub.2, W and X of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving in |
| 7279472 |
Compounds useful as reversible inhibitors of cysteine proteases |
October 9, 2007 |
| Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds ##STR00001## |
| 7276491 |
Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors |
October 2, 2007 |
| Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors. |
| 7268152 |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
September 11, 2007 |
| Compounds of Formula (IA) and Formula (IB) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and |
| 7265222 |
Process of making di-aryl urea compounds |
September 4, 2007 |
| Disclosed is a process of making compounds of formula(I): ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ra of formula(I) are defined herein. The product compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating disease |
| 7265132 |
Compounds useful as reversible inhibitors of cysteine proteases |
September 4, 2007 |
| Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds ##STR00001## |
| 7256314 |
Method for generating secondary phosphines |
August 14, 2007 |
| This invention provides a method for generating secondary phosphines from secondary phosphine oxides in the presence of a reducing agent, such as diisobutylaluminum hydride (DIBAL-H), triisobutyldialuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, or another reducing agent |
| 7256300 |
Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
August 14, 2007 |
| A process for stereoselective synthesis of a compound of Formula (X) or Formula (X') ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, the process comprising: (a) reacting the starting material of formula A with a chiral sulfoxide anion source in a suitable s |
| 7241758 |
Compounds useful as anti-inflammatory agents |
July 10, 2007 |
| Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are |
| 7235654 |
Methods for modulating IKK.alpha. activity |
June 26, 2007 |
| A method for modulating NF-.kappa.B dependent gene transcription in a cell comprised of modulating IKK.alpha. protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-.kappa.B dependent gene transcription. |
| 7222792 |
Method and system for assisted culling and reformatting of encoded microtubes |
May 29, 2007 |
| A method and system for aiding the selecting/culling or reformatting of encoded containers stored in a multi-rack array with respect to certain desired characteristics of compositions held within the containers employing a corresponding graphical interface that indicates the physical |
| 7214802 |
Anti-cytokine heterocyclic compounds |
May 8, 2007 |
| Disclosed compounds of formula (I) ##STR00001## which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for |
| 7211575 |
Methods of treating cytokine mediated diseases |
May 1, 2007 |
| Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, conges |
| 7189758 |
Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof |
March 13, 2007 |
| A compound of Formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor |
| 7186864 |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
March 6, 2007 |
| A compound of Formula (IA) or Formula (IB) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of m |
| 7186827 |
Dipeptide synthesis |
March 6, 2007 |
| Disclosed are processes of making dipeptide compounds of formula(I) as further described in the detailed description section: ##STR00001## |
| 7179919 |
Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
February 20, 2007 |
| A process for stereoselective synthesis of a compound of Formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as described herein. |
| 7173028 |
Pyrimidine derivatives |
February 6, 2007 |
| The present invention relates to trisubstituted pyrimidines of formula (I) ##STR00001## wherein 0R.sub.a to R.sub.e are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a |
| 7166628 |
Cytokine inhibitors |
January 23, 2007 |
| Disclosed are compounds of formula (I) ##STR00001## Where Ar.sub.1, X, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological |
| 7138420 |
Substituted benzimidazole compounds |
November 21, 2006 |
| Disclosed are substituted benzimidazole compounds of formula (I): ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X.sub.a are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions invo |
| 7125996 |
Fluorescent probes for use in protein kinase inhibitor binding assay |
October 24, 2006 |
| The invention provides methods relating to a novel screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The K.sub.d for the i |
| 7119102 |
Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for pr |
October 10, 2006 |
| Disclosed are compounds of formula (I): ##STR00001## wherein the variables R.sub.1, R.sub.2, R.sub.3 and Z are described herein, which are useful as inhibitors of the kinase activity of the I.kappa.B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK me |
| 7115644 |
Heterocyclic compounds |
October 3, 2006 |
| Disclosed are benzimidazolone compounds of formulas (I) & (II):wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and path |
| 7091340 |
Polymorphs |
August 15, 2006 |
| Disclosed are polymorphs of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)- -naphthalen-1-yl]-urea and processes from making the same. |
| 7084118 |
Combination treatment with t-PA variant and low molecular weight heparin |
August 1, 2006 |
| The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activ |
| 7078419 |
Cytokine inhibitors |
July 18, 2006 |
| Disclosed are compounds of formula (I) ##STR00001## Where Ar.sub.1, X, Y, Q, W, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.y are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases |
| 7074806 |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
July 11, 2006 |
| A compound of Formula (IA) or Formula (IB) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein, or a tautomer prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of mod |
| 7056915 |
Compounds useful as reversible inhibitors of cysteine proteases |
June 6, 2006 |
| Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds ##STR00001## |
| 7045346 |
Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell |
May 16, 2006 |
| Unique multifunctional nucleotide expression cassettes comprising a nucleotide sequence encoding a human protease driven by a glucose-regulatable promoter, a nucleotide sequence encoding human proinsulin having sites at its B-C and C-A junctions altered to permit cleavage by the huma |
| 7041669 |
1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
May 9, 2006 |
| Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I): ##STR00001## wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathol |
| 7026476 |
Intermediate arylamine compounds |
April 11, 2006 |
| Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are and pharmaceutical compositions containing, intermediate compounds and processes of making such co |
| 7022883 |
Preparation of aryl intermediates |
April 4, 2006 |
| Disclosed are methods of making aryl intermediate compounds of the formula (A) which are useful in the production of heteroaryl ureas, ##STR00001## Y and P are defined herein below. |
| 7019006 |
Compounds useful as anti-inflammatory agents |
March 28, 2006 |
| Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds. |
